STOCK TITAN
  1. Home
  2. News
  3. TENX

Tenax Therapeutics, Inc. - $TENX STOCK NEWS

Welcome to our dedicated page for Tenax Therapeutics news (Ticker: $TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tenax Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tenax Therapeutics's position in the market.

News

Tenax Therapeutics Announces Reverse Stock Split

Rhea-AI Summary
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced a 1-for-80 reverse stock split aimed at addressing Nasdaq's minimum bid price requirement. The reverse split will reduce outstanding shares from 23,862,434 to approximately 292,281, with no change to authorized shares or par value per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.79%
Tags
none
-
News

Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board

Rhea-AI Summary
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced the appointment of Javed Butler, M.D., M.P.H, M.B.A., to the Company’s PH-HFpEF Scientific Advisory Board. Dr. Butler, a renowned clinical trialist in cardiovascular medicine, will join the distinguished SAB overseeing the development of levosimendan. This follows the FDA clearance of Tenax’s planned Phase 3 investigation of oral levosimendan in PH-HFpEF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.29%
Tags
management
-
News

Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

Rhea-AI Summary
Tenax Therapeutics, Inc. (Nasdaq: TENX) announces FDA clearance for Phase 3 study of TNX-103 in PH-HFpEF patients, with the first study, The LEVEL Study, set to commence in 4Q 2023. The FDA has agreed that 6MWD will be the primary endpoint for both Phase 3 studies. The Phase 3 program is designed to meet FDA's request for subject drug exposure of 300 patients for 6 months and 100 patients for 1 year. Oral levosimendan use in PH-HFpEF is protected by a USPTO granted patent until 2040. There are no FDA-approved treatments for PH-HFpEF, with an estimated prevalence of more than 2,000,000 patients in North America by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
297.44%
Tags
clinical trial
News

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Rhea-AI Summary
Tenax Therapeutics, Inc. (Nasdaq: TENX) - New U.S. patent granted for oral levosimendan (TNX-103) in the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) until December 2040. The patent broadens Tenax’s U.S. IP protection and covers the use of oral levosimendan for the treatment of PH-HFpEF, with potential to generate billions in future estimated annual sales. TNX-103, the only drug to show statistically significant improvement in the 6-minute walk endpoint in Phase 2 HELP Study, will initiate a Phase 3 trial in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.51%
Tags
none
-
News

Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.44%
Tags
none
-
News

Tenax Therapeutics Provides 2023 Business Update

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
News

Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
none
-
News

Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.81%
Tags
offering
-
News

Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.77%
Tags
none
News

Tenax Therapeutics Announces Reverse Stock Split

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock TENX logo
Tenax Therapeutics, Inc.

Nasdaq:TENX

TENX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

TENX Stock Data

6.87M
1.84M
0.36%
4.08%
2.5%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CHAPEL HILL

About TENX

tenax therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions. our development portfolio includes novel product candidates that have the potential to address various critical care conditions with high unmet medical need.